Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Herbal Supplements Market

This article was originally published in The Tan Sheet

Executive Summary

U.S. retail sales of herbal supplements could approach $6 bil. in 2006, up from $4.1 bil. in 2000 and $2.8 bil. in 1996, a compound annual growth rate of 6%, Datamonitor forecasts in a consumer trends analysis released Aug. 6. The markets for herbal supplements, vitamins and minerals, and OTC drugs all benefit from consumers' growing concerns about health, reflected in an increased interest in self-medication and adoption of health regimens. Datamonitor notes that "functional health" products, such as nutraceuticals, have "substantially outperformed the level of overall market growth and this trend is expected to continue," with annual U.S. retail sales projected to reach about $3.5 bil. in 2007. Additional factors driving consumer spending include convenience, age complexity (children acting older, adults acting younger), individualism, and sensory appeal, according to the 1"Global Consumer Trends" report. Details and purchasing information are available by contacting 800-759-0261 or

You may also be interested in...

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts